Mitoconix Bio Company

Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases. Mitoconix’ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntington’s (HD) and Parkinson’s diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimer’s disease (AD).
Technology: Other
Industry: Mitochondrial Dynamics
Headquarters: Israel
Founded Date: 2016
Investors Number: 6
Total Funding: $54.2M
Estimated Revenue: Less than $1M
Last Funding Type: Venture - Series Unknown

Visit Website
Register and Claim Ownership